The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Targeted therapies for gastroesophageal adenocarcinoma
Daniel Catenacci, MD, University of Chicago, Chicago, IL, talks on the targeted therapy treatment landscape for patients with gastroesophageal adenocarcinoma including the use of HER2-targeting agents, as well as the development of molecular biomarkers of response to immune checkpoint blockade. In addition, Dr Catenacci highlights claudin as a valuable biomarker, and the use of zolbetuximab, a monoclonal antibody targeting claudin which has shown efficacy in metastatic gastric or gastroesophageal junction adenocarcinoma and is currently being evaluated in two Phase III trials, SPOTLIGHT (NCT03504397) and GLOW (NCT03653507). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Daniel Catenacci, MD has received support/funding from Genentech/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Gritstone, Pieris, Zymeworks, Basilea, QED, Arcus, Foundation Medicine, Tempus, Guardant Health, Archer & Natera.
